Form 4: Neurogene Inc. President and CFO Sells Shares to Cover Tax Obligations

Christine Mikail Cvijic, President and CFO of Neurogene Inc., sold 4,501 shares of common stock on March 13, 2025, to cover tax withholding obligations related to the vesting of a Restricted Stock Unit (RSU).

Summary

• On March 13, 2025, Christine Mikail Cvijic, the President and CFO of Neurogene Inc., sold 4,501 shares of the company's common stock.
• The sale was executed to cover tax withholding responsibilities arising from the vesting of a Restricted Stock Unit (RSU).
• The shares were sold at a weighted average price of $16.94, with individual transactions ranging from $16.38 to $17.21.
• Following the transaction, Cvijic directly owns 72,343 shares of Neurogene Inc., which includes 24,000 shares held jointly with her spouse, David Cvijic.

Sentiment

Score: 5

Explanation: The document reflects a neutral sentiment as it reports a routine transaction related to tax obligations. It doesn't indicate any positive or negative outlook for the company.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives. This transaction is a routine event and doesn't necessarily indicate a change in the executive's confidence in the company.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units (RSUs) to align management's interests with those of shareholders.
• The sale of shares to cover tax obligations upon vesting is a standard practice across various industries and companies, including pharmaceutical and biotechnology firms.
• Comparable companies such as BioMarin Pharmaceutical and Sarepta Therapeutics also see similar transactions by their executives.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant effect given the reason for the sale.

Key Dates